Axsome Therapeutics Inc AXSM

Morningstar Rating
$135.95 −1.06 (0.77%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

AXSM is trading at a LOCK|GHS^r$ premium.
Price
$137.01
Fair Value
LOCK|x.>y@rrCFT
Uncertainty
LOCK|lV&
1-Star Price
LOCK|B.@@!&^Q$
5-Star Price
LOCK|@.sh%LvJq
Economic Moat
LOCK|R@>
Capital Allocation
—

News

Trading Information

Previous Close Price
$137.01
Day Range
$134.61–137.49
52-Week Range
$123.00–260.19
Bid/Ask
$125.40 / $138.50
Shares Outstanding
52.60M
Market Cap
$7.15B
Volume/Avg
518,111 / 855,673

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
8.16
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
925

Valuation

Metric
AXSM
Price/Earnings (Normalized)
—
Price/Book Value
68.32
Price/Sales
8.16
Price/Cash Flow
—
Price/Earnings
No chart available

Financial Strength

Metric
AXSM
Quick Ratio
1.29
Current Ratio
1.42
Interest Coverage
−26.88
Quick Ratio
AXSM

Profitability

Metric
AXSM
Return on Assets (Normalized)
−12.61%
Return on Equity (Normalized)
−113.85%
Return on Invested Capital (Normalized)
−29.16%
Return on Assets
AXSM

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|h?&lCd%LOCK|h%wMp$136B
Regeneron Pharmaceuticals Inc
REGN
LOCK|!jv@#R&LOCK|!r^n>$99B
Moderna Inc
MRNA
LOCK|F@^PSGkLOCK|#^$87B
argenx SE ADR
ARGX
LOCK|J<@WtmLOCK|^zm$61B
BeOne Medicines Ltd ADR
ONC
LOCK|X@Wg^SLOCK|&m$48B
Royalty Pharma PLC Class A
RPRX
LOCK|!%tq?<B&LOCK|F#sGS$31B
Incyte Corp
INCY
LOCK|<#V!P#LOCK|tr@$25B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|?h>FJ?LOCK|$?ct&$21B
BioNTech SE ADR
BNTX
LOCK|NK!>HbLOCK|NR^$21B
Jazz Pharmaceuticals PLC
JAZZ
LOCK|c!qx!<LOCK|x&d$15B

Sponsor Center